1.46
price up icon1.39%   0.02
pre-market  Vorhandelsmarkt:  1.46  
loading
Schlusskurs vom Vortag:
$1.44
Offen:
$1.44
24-Stunden-Volumen:
1.83M
Relative Volume:
0.70
Marktkapitalisierung:
$530.56M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.825
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
-3.95%
1M Leistung:
+26.96%
6M Leistung:
+175.47%
1J Leistung:
-18.44%
1-Tages-Spanne:
Value
$1.4215
$1.485
1-Wochen-Bereich:
Value
$1.40
$1.66
52-Wochen-Spanne:
Value
$0.2836
$2.175

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name
Firmenname
Lexicon Pharmaceuticals Inc
Name
Telefon
(281) 863-3000
Name
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Name
Mitarbeiter
103
Name
Twitter
@LexPharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
LXRX's Discussions on Twitter

Vergleichen Sie LXRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LXRX
Lexicon Pharmaceuticals Inc
1.46 541.46M 1.21M -177.12M -162.37M -0.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
412.22 104.45B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
469.36 60.95B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.60 59.11B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.95 49.23B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.94 35.92B 4.56B -176.77M 225.30M -1.7177

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-05 Herabstufung Leerink Partners Outperform → Market Perform
2024-06-17 Eingeleitet H.C. Wainwright Buy
2024-04-30 Eingeleitet Leerink Partners Outperform
2023-03-07 Eingeleitet Jefferies Hold
2022-08-12 Eingeleitet Piper Sandler Overweight
2021-01-29 Hochstufung JP Morgan Underweight → Neutral
2021-01-29 Herabstufung Wedbush Outperform → Neutral
2020-12-08 Hochstufung Citigroup Neutral → Buy
2020-11-18 Hochstufung Gabelli & Co Hold → Buy
2019-12-11 Herabstufung Gabelli & Co Buy → Hold
2019-11-08 Herabstufung Citigroup Buy → Neutral
2019-09-11 Hochstufung Gabelli & Co Hold → Buy
2019-07-29 Herabstufung Stifel Buy → Hold
2019-03-25 Hochstufung Gabelli & Co Sell → Hold
2018-07-31 Bestätigt Stifel Buy
2018-02-23 Herabstufung Needham Buy → Hold
2018-02-14 Herabstufung JP Morgan Neutral → Underweight
2017-03-01 Bestätigt H.C. Wainwright Buy
2017-03-01 Bestätigt Wedbush Outperform
2016-10-07 Eingeleitet H.C. Wainwright Buy
2016-08-05 Bestätigt Wedbush Outperform
2016-08-02 Eingeleitet Citigroup Buy
2016-03-02 Bestätigt Wedbush Outperform
2015-11-09 Bestätigt Wedbush Outperform
2015-09-28 Hochstufung Gabelli & Co Sell → Hold
2015-09-18 Herabstufung Gabelli & Co Hold → Sell
2015-08-10 Herabstufung JP Morgan Overweight → Neutral
Alle ansehen

Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten

pulisher
Oct 14, 2025

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit - The Manila Times

Oct 14, 2025
pulisher
Oct 14, 2025

Short interest data insights for Lexicon Pharmaceuticals Inc.2025 Geopolitical Influence & AI Enhanced Trading Signals - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

Is Lexicon Pharmaceuticals Inc. stock attractive for hedge fundsWeekly Loss Report & Free Low Drawdown Momentum Trade Ideas - newser.com

Oct 14, 2025
pulisher
Oct 13, 2025

Is Lexicon Pharmaceuticals Inc. building a consolidation baseMarket Sentiment Summary & Reliable Price Action Trade Plans - newser.com

Oct 13, 2025
pulisher
Oct 10, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8% HigherWhat's Next? - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Lexicon Pharmaceuticals' (LXRX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 08, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Down 6.3%Time to Sell? - MarketBeat

Oct 08, 2025
pulisher
Oct 08, 2025

Lexicon (LXRX) Engages in Policy Discussion to Tackle Chronic Pa - GuruFocus

Oct 08, 2025
pulisher
Oct 08, 2025

Lexicon Pharmaceuticals Hosts Roundtable on Legislative Solutions for Chronic Pain Management - Quiver Quantitative

Oct 08, 2025
pulisher
Oct 08, 2025

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - MarketScreener

Oct 08, 2025
pulisher
Oct 08, 2025

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People With Chronic Pain - 富途牛牛

Oct 08, 2025
pulisher
Oct 06, 2025

Detecting price anomalies in Lexicon Pharmaceuticals Inc. with AIEarnings Beat & Intraday High Probability Alerts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Can you recover from losses in Lexicon Pharmaceuticals Inc.2025 Analyst Calls & Safe Entry Point Identification - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Is Lexicon Pharmaceuticals Inc. a candidate for recovery playPortfolio Value Summary & Consistent Income Trade Recommendations - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Oct 04, 2025
pulisher
Oct 03, 2025

Is Lexicon Pharmaceuticals Inc. stock bottoming out2025 Risk Factors & Weekly Watchlist for Consistent Profits - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

What’s the recovery path for long term holders of Lexicon Pharmaceuticals Inc.Portfolio Return Summary & Long-Term Capital Growth Ideas - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Smart tools for monitoring Lexicon Pharmaceuticals Inc.’s price actionGap Up & High Accuracy Investment Signals - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Lexicon Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Affordable Trading Portfolio - earlytimes.in

Oct 02, 2025
pulisher
Oct 02, 2025

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28% - simplywall.st

Oct 02, 2025
pulisher
Sep 30, 2025

Lexicon Pharmaceuticals, Inc. $LXRX Stake Reduced by Goldman Sachs Group Inc. - MarketBeat

Sep 30, 2025
pulisher
Sep 28, 2025

What analysts say about Lexicon Pharmaceuticals Inc stockContrarian Investment Ideas & Big Gains Low Budget - earlytimes.in

Sep 28, 2025
pulisher
Sep 26, 2025

Lexicon reports FDA's decision to extend review period for Zynquista - MSN

Sep 26, 2025
pulisher
Sep 24, 2025

Lexicon Pharmaceuticals, Inc. $LXRX Shares Purchased by Compagnie Lombard Odier SCmA - MarketBeat

Sep 24, 2025
pulisher
Sep 23, 2025

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes - MarketScreener

Sep 23, 2025
pulisher
Sep 23, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Sep 23, 2025
pulisher
Sep 22, 2025

Lexicon awaits FDA feedback on diabetes drug application in Q4 By Investing.com - Investing.com Australia

Sep 22, 2025
pulisher
Sep 22, 2025

Lexicon awaits FDA feedback on diabetes drug application in Q4 - Investing.com

Sep 22, 2025
pulisher
Sep 22, 2025

Lexicon Pharmaceuticals (LXRX) Faces FDA Review Extension for Zy - GuruFocus

Sep 22, 2025

Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Lexicon Pharmaceuticals Inc-Aktie (LXRX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Sullivan Diane E.
Director
May 13 '25
Option Exercise
0.00
36,810
0
36,810
SOBECKI CHRISTOPHER J
Director
May 13 '25
Option Exercise
0.00
36,810
0
203,865
BARKER SAM L
Director
May 13 '25
Option Exercise
0.00
36,810
0
124,459
Amouyal Philippe
Director
May 13 '25
Option Exercise
0.00
36,810
0
285,174
DEBBANE RAYMOND
Director
May 13 '25
Option Exercise
0.00
36,810
0
1,385,689
$21.75
price down icon 5.15%
$85.96
price up icon 1.45%
$32.75
price up icon 0.21%
$102.61
price up icon 0.30%
$161.38
price down icon 1.56%
biotechnology ONC
$320.94
price down icon 1.86%
Kapitalisierung:     |  Volumen (24h):